November 20, 2025
OXFORD, UK and CLEVELAND, Ohio, US, 20 November 2025 – The Oxford-Harrington Rare Disease Centre (‘OHC’) today announced the recipients of the 2025 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice. Each Scholar will receive an advisory team providing...
Continue ReadingApril 13, 2016
WILMINGTON, MA, April 13, 2016 – Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development. Through this partnership, Charles River will... Continue Reading
March 15, 2016
2016 Harrington Prize for Innovation in Medicines Recognizes Discovery of Leptin and the Leptin-Mediated Pathway Continue Reading
February 29, 2016
Formed by BioMotiv and Rutgers UniversityCLEVELAND AND NEW BRUNSWICK— FEBRUARY 29, 2016— BioMotiv, a drug development accelerator associated with The Harrington Project, and Rutgers, the State University of New Jersey, are announcing the formation of a new biotechnology startup, Z53 Therapeutics. Z53 Therapeutics aims to... Continue Reading
February 11, 2016
Dr. Jonathan Stamler, director of The Harrington Discovery Institute at University Hospitals in Cleveland, has earned a reputation as a “genius.”“Some people are geniuses,” his fatherâinâlaw Norman Wain said. “Geniuses have a capacity to work.”“He has this sort of infectious personality to want to drive... Continue Reading
January 13, 2016
Cleveland, Ohio – The Harrington Discovery Institute at University Hospitals (UH) in Cleveland, Ohio has announced the 2016 recipients of Harrington Scholar-Innovator Awards. The awards support breakthrough work of physician-scientists whose discovery research shows promise of advancing the standard of care.The Harrington... Continue Reading
January 08, 2016
Cleveland– January 8, 2016 – Dual Therapeutics, LLC (“Dual Therapeutics”) today announced a strategic collaboration with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds for the treatment of cancer and other diseases. Dual Therapeutics’ small-molecule modulators simultaneously block multiple cancer... Continue Reading
May 01, 2015
- 2015 Harrington Scholar-Innovator Continue Reading
May 01, 2015
- 2015 Harrington Scholar-Innovator Continue Reading
May 01, 2015
- 2015 Oxford-Harrington Scholar Continue Reading
May 01, 2015
- 2015 ADDF-Harrington Scholar Continue Reading